Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
9,51 USD | -0,83% |
|
-5,94% | -20,08% |
Vakgebied
De netto-omzet is geografisch als volgt verdeeld: Japan (28,8%), Noord- en Zuid-Amerika (34,5%) en overige (36,7%).
Aantal werknemers: 14 484
Verkoop per activiteit
JPY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Pharmaceutical
100,0
%
| 1 296 163 | 100,0 % | 1 518 619 | 100,0 % | +17,16% |
Verkoop per regio
JPY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
43,0
%
| 537 452 | 41,5 % | 652 441 | 43,0 % | +21,40% |
Established Markets
23,6
%
| 315 162 | 24,3 % | 358 407 | 23,6 % | +13,72% |
Japan
17,3
%
| 258 758 | 20,0 % | 262 303 | 17,3 % | +1,37% |
International
9,5
%
| 110 081 | 8,5 % | 144 735 | 9,5 % | +31,48% |
Greater China
5,3
%
| 66 305 | 5,1 % | 80 011 | 5,3 % | +20,67% |
Other
1,4
%
| 8 406 | 0,6 % | 20 722 | 1,4 % | +146,51% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Naoki Okamura
CEO | Chief Executive Officer | 61 | 01-04-86 |
Kitamura Atsushi
DFI | Director of Finance/CFO | 52 | 01/11 |
Kenji Yasukawa
CHM | Chairman | 64 | 01-04-86 |
Compliance Officer | - | 01-10-22 | |
Chief Tech/Sci/R&D Officer | - | - | |
Chief Tech/Sci/R&D Officer | - | - | |
Director/Board Member | 65 | 01-09-06 | |
Noriyuki Uematsu
BRD | Director/Board Member | 64 | 01-06-16 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 01-04-83 |
Atsushi Kamide
IRO | Public Communications Contact | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Takashi Tanaka
BRD | Director/Board Member | 67 | 01-06-21 |
Mamoru Sekiyama
BRD | Director/Board Member | 74 | 01-06-17 |
Kenji Yasukawa
CHM | Chairman | 64 | 01-04-86 |
Noriyuki Uematsu
BRD | Director/Board Member | 64 | 01-06-16 |
Haruko Shibumura
BRD | Director/Board Member | 59 | 01-06-19 |
Hiroko Sakai
BRD | Director/Board Member | 63 | 01-04-83 |
Hiroo Sasaki
BRD | Director/Board Member | 68 | 01-06-18 |
Hiroshi Kawabe
BRD | Director/Board Member | 72 | 01-06-19 |
Mika Nakayama
BRD | Director/Board Member | - | - |
Compliance Officer | - | 01-10-22 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 1 809 663 075 | 1 788 620 803 ( 98,84 %) | 16 561 677 ( 0,9152 %) | 98,84 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
7 266 342 | 3.89% | 24 923 553 $ | |
8 333 333 | 8.59% | 24 916 666 $ | |
ASTELLAS PHARMA INC. 0.04% | 731 000 | 0.04% | 7 203 245 $ |
FIBROGEN, INC. 4.99% | 4 968 367 | 4.99% | 5 962 040 $ |
ONCOLYS BIOPHARMA INC. 3.47% | 727 200 | 3.47% | 3 040 314 $ |
Bedrijfsgegevens
Astellas Pharma, Inc.
2-5-1 Nihonbashi-Honcho Chuo-Ku
103-8411, Tokyo
+81 3 3244 3000
http://www.astellas.com![Adres Astellas Pharma Inc.(ALPMY)](https://cdn.zonebourse.com/static/address/120791908.png)
Bedrijven van de groep
Naam | Categorie en sector |
---|---|
Astellas BV
![]() Astellas BV Financial ConglomeratesFinance Part of Astellas Pharma, Inc., Astellas BV is a Dutch company that functions as an investment holding company. The company is based in Leiden, Netherlands. |
Financial Conglomerates
|
Sector
Verkoop per regio
![Consensus](/images/consensus_flch.gif)
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,96% | 630 mld. | |
-7,15% | 350 mld. | |
+18,77% | 328 mld. | |
+8,79% | 298 mld. | |
+18,02% | 246 mld. | |
+1,27% | 225 mld. | |
+11,95% | 218 mld. | |
+3,68% | 160 mld. | |
-4,38% | 156 mld. |
- Beurs
- Aandelen
- Koers 4503
- Koers ALPMY
- Onderneming Astellas Pharma Inc.